Review



dcas9 dnmt3a puror v2  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Addgene inc dcas9 dnmt3a puror v2
    Dcas9 Dnmt3a Puror V2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas9+dnmt3a/pdCas9-DNMT3A-PuroR_v2+(Plasmid+%2374407)/bio_rxiv__64898__2026__10__27__762200-447-18-19
    Average 93 stars, based on 12 article reviews
    dcas9 dnmt3a puror v2 - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Plasmid Preparation:

    Article Title: Defining Mechanistic Links Between the Non-Coding Variant rs17673553 in CLEC16A and Lupus Susceptibility
    Article Snippet: .. We co-transfected the guide RNA-containing plasmid (VectorBuilder) along with CRISPRa plasmids dCas9-VPR and dCas9-TET1 (Addgene), and CRISPRi plasmids dCas9-KRAB-MECP2 and dCas9-DNMT3A (Addgene) in a 1:3 ratio. .. Samples were harvested 48 hours post-transfection, RNA was extracted using the Quick-RNA mini kit (Zymo Research), and cDNA was synthesized using the iScript (Bio-Rad) system.

    Article Title: Defining Mechanistic Links Between the Non-Coding Variant rs17673553 in CLEC16A and Lupus Susceptibility.
    Article Snippet: .. We co-transfected the guide RNA-containing plasmid (VectorBuilder: Neu-Isenburg, Germany) along with CRISPRa plasmids dCas9-VPR and dCas9-TET1 (Addgene: Watertown, MA, USA), and CRISPRi plasmids dCas9-KRABMECP2 and dCas9-DNMT3A (Addgene) in a 1:3 ratio. .. Samples were harvested 48 h post-transfection, RNA was extracted using the Quick-RNA mini kit (Zymo Research: Irvine, CA, USA), and cDNA was synthesized using the iScript (Bio-Rad: Hercules, CA, USA) system.

    Article Title: Defining Mechanistic Links Between the Non-Coding Variant rs17673553 in CLEC16A and Lupus Susceptibility
    Article Snippet: .. We co-transfected the guide RNA-containing plasmid (VectorBuilder: Neu-Isenburg, Germany) along with CRISPRa plasmids dCas9-VPR and dCas9-TET1 (Addgene: Watertown, MA, USA), and CRISPRi plasmids dCas9-KRAB-MECP2 and dCas9-DNMT3A (Addgene) in a 1:3 ratio. .. Samples were harvested 48 h post-transfection, RNA was extracted using the Quick-RNA mini kit (Zymo Research: Irvine, CA, USA), and cDNA was synthesized using the iScript (Bio-Rad: Hercules, CA, USA) system.

    Article Title: Hypoxia-induced CTCF mediates alternative splicing via coupling chromatin looping and RNA Pol II pause to promote EMT in breast cancer.
    Article Snippet: The designed sgRNA were cloned into dCas9_DNMT3A (Addgene #74407) expression vectors as described previously40,86 using BpiI/BbsI (Fermentas, Cat No. ER1012). .. Additionally, Addgene #71830 plasmid having non-targeting (NT) control guide RNAs (sgcontrol) was used as a control for dCas9-DNMT3A system. .. Additionally, Addgene #71830 plasmid having non-targeting (NT) control guide RNAs (sgcontrol) was used as a control for dCas9-DNMT3A system.

    Clone Assay:

    Article Title: Hypoxia-induced CTCF mediates alternative splicing via coupling chromatin looping and RNA Pol II pause to promote EMT in breast cancer.
    Article Snippet: Next, for rescue experiments, CTCF depleted cells were transfected with COL5A1exon64A or COL5A1exon64B transcript overexpression plasmid using Lipofectamine 2000 reagent (Invitrogen, 11668019) as per the manufacturer’s instructions. sgRNA designing and cloning in dCas9-DNMT3A expression vector and cell transfections GT-Scan web-tool (http://gt-scan.braembl.org.au/gt-scan/ 64) and CRISPick (https://portals.broadinstitute.org/gppx/crispick/ public65) were used to design guide sequences targeting the loci of interest. .. The designed sgRNA were cloned into dCas9_DNMT3A (Addgene #74407) expression vectors as described previously40,86 using BpiI/BbsI (Fermentas, Cat No. ER1012). .. Additionally, Addgene #71830 plasmid having non-targeting (NT) control guide RNAs (sgcontrol) was used as a control for dCas9-DNMT3A system.

    Expressing:

    Article Title: Hypoxia-induced CTCF mediates alternative splicing via coupling chromatin looping and RNA Pol II pause to promote EMT in breast cancer.
    Article Snippet: Next, for rescue experiments, CTCF depleted cells were transfected with COL5A1exon64A or COL5A1exon64B transcript overexpression plasmid using Lipofectamine 2000 reagent (Invitrogen, 11668019) as per the manufacturer’s instructions. sgRNA designing and cloning in dCas9-DNMT3A expression vector and cell transfections GT-Scan web-tool (http://gt-scan.braembl.org.au/gt-scan/ 64) and CRISPick (https://portals.broadinstitute.org/gppx/crispick/ public65) were used to design guide sequences targeting the loci of interest. .. The designed sgRNA were cloned into dCas9_DNMT3A (Addgene #74407) expression vectors as described previously40,86 using BpiI/BbsI (Fermentas, Cat No. ER1012). .. Additionally, Addgene #71830 plasmid having non-targeting (NT) control guide RNAs (sgcontrol) was used as a control for dCas9-DNMT3A system.

    Control:

    Article Title: Hypoxia-induced CTCF mediates alternative splicing via coupling chromatin looping and RNA Pol II pause to promote EMT in breast cancer.
    Article Snippet: The designed sgRNA were cloned into dCas9_DNMT3A (Addgene #74407) expression vectors as described previously40,86 using BpiI/BbsI (Fermentas, Cat No. ER1012). .. Additionally, Addgene #71830 plasmid having non-targeting (NT) control guide RNAs (sgcontrol) was used as a control for dCas9-DNMT3A system. .. Additionally, Addgene #71830 plasmid having non-targeting (NT) control guide RNAs (sgcontrol) was used as a control for dCas9-DNMT3A system.



    Similar Products

    93
    Addgene inc dcas9 dnmt3a puror v2
    Dcas9 Dnmt3a Puror V2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas9+dnmt3a/pdCas9-DNMT3A-PuroR_v2+(Plasmid+%2374407)/bio_rxiv__64898__2026__10__27__762200-447-18-19
    Average 93 stars, based on 1 article reviews
    dcas9 dnmt3a puror v2 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Addgene inc dcas9 dnmt3a vector
    CTCF is required for optimal GLUT3 expression under hypoxia. A) mRNA expression of glycolysis genes in sh_control under normoxia and hypoxia and sh_CTCF under hypoxia in MCF7 cells inferred from CTCF depletion RNA-seq B) genome browser view of SLC2A3 loci of CTCF-ChIP-seq and RNA-seq under normoxia and hypoxia and of RNA-seq in shcontrol and shCTCF under hypoxia in MCF7 cells C) UMAP plot of breast epithelial cancerous cell populations stratified as continuous hypoxic state using Buffa score highlighting CTCF expression and SLC2A3 expression D) Schematic representation of targeting the CTCF motif present in the SLC2A3/GLUT3 promoter region by <t>dCas9-DNMT3A</t> with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy E-G) E and F) MeDIP-qPCR and CTCF-ChIP-qPCR on GLUT3 promoter E) MCF7 and F) MDA-MB-231 (G) immunoblot of GLUT3 in MCF7 and MDA-MB-231cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia (H) Schematic showing hypoxia-driven epigenetic and transcriptional regulation of GLUT3 expression in breast cancer. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired, two-tailed Welch’s Two-Sample t-test (A), Co-expression was assessed using Fisher’s exact test (odds ratio [OR] = 1.80, p < 2.2 × 10⁻¹⁶) (C), unpaired two-tailed Student’s t-tests (F and G), *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
    Dcas9 Dnmt3a Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas9+dnmt3a/pdCas9-DNMT3A-PuroR_hNT+(Plasmid+%2371830)/bio_rxiv__64898__2026__10__27__762200-448-3-5
    Average 93 stars, based on 1 article reviews
    dcas9 dnmt3a vector - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    Addgene inc dcas9
    CTCF is required for optimal GLUT3 expression under hypoxia. A) mRNA expression of glycolysis genes in sh_control under normoxia and hypoxia and sh_CTCF under hypoxia in MCF7 cells inferred from CTCF depletion RNA-seq B) genome browser view of SLC2A3 loci of CTCF-ChIP-seq and RNA-seq under normoxia and hypoxia and of RNA-seq in shcontrol and shCTCF under hypoxia in MCF7 cells C) UMAP plot of breast epithelial cancerous cell populations stratified as continuous hypoxic state using Buffa score highlighting CTCF expression and SLC2A3 expression D) Schematic representation of targeting the CTCF motif present in the SLC2A3/GLUT3 promoter region by <t>dCas9-DNMT3A</t> with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy E-G) E and F) MeDIP-qPCR and CTCF-ChIP-qPCR on GLUT3 promoter E) MCF7 and F) MDA-MB-231 (G) immunoblot of GLUT3 in MCF7 and MDA-MB-231cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia (H) Schematic showing hypoxia-driven epigenetic and transcriptional regulation of GLUT3 expression in breast cancer. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired, two-tailed Welch’s Two-Sample t-test (A), Co-expression was assessed using Fisher’s exact test (odds ratio [OR] = 1.80, p < 2.2 × 10⁻¹⁶) (C), unpaired two-tailed Student’s t-tests (F and G), *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
    Dcas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas9+dnmt3a/DNMT3A-dCas9+(Plasmid+%23100090)/pm41620608-255-11-18
    Average 95 stars, based on 1 article reviews
    dcas9 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Addgene inc m3 dcas9 dnmt3a krab
    CTCF is required for optimal GLUT3 expression under hypoxia. A) mRNA expression of glycolysis genes in sh_control under normoxia and hypoxia and sh_CTCF under hypoxia in MCF7 cells inferred from CTCF depletion RNA-seq B) genome browser view of SLC2A3 loci of CTCF-ChIP-seq and RNA-seq under normoxia and hypoxia and of RNA-seq in shcontrol and shCTCF under hypoxia in MCF7 cells C) UMAP plot of breast epithelial cancerous cell populations stratified as continuous hypoxic state using Buffa score highlighting CTCF expression and SLC2A3 expression D) Schematic representation of targeting the CTCF motif present in the SLC2A3/GLUT3 promoter region by <t>dCas9-DNMT3A</t> with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy E-G) E and F) MeDIP-qPCR and CTCF-ChIP-qPCR on GLUT3 promoter E) MCF7 and F) MDA-MB-231 (G) immunoblot of GLUT3 in MCF7 and MDA-MB-231cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia (H) Schematic showing hypoxia-driven epigenetic and transcriptional regulation of GLUT3 expression in breast cancer. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired, two-tailed Welch’s Two-Sample t-test (A), Co-expression was assessed using Fisher’s exact test (odds ratio [OR] = 1.80, p < 2.2 × 10⁻¹⁶) (C), unpaired two-tailed Student’s t-tests (F and G), *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
    M3 Dcas9 Dnmt3a Krab, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas9+dnmt3a/DNMT3A-dCas9+(Plasmid+%23100090)/pm41620608-258-2-4
    Average 95 stars, based on 1 article reviews
    m3 dcas9 dnmt3a krab - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Addgene inc dcas9 dnmt3a plasmid
    CTCF is required for optimal GLUT3 expression under hypoxia. A) mRNA expression of glycolysis genes in sh_control under normoxia and hypoxia and sh_CTCF under hypoxia in MCF7 cells inferred from CTCF depletion RNA-seq B) genome browser view of SLC2A3 loci of CTCF-ChIP-seq and RNA-seq under normoxia and hypoxia and of RNA-seq in shcontrol and shCTCF under hypoxia in MCF7 cells C) UMAP plot of breast epithelial cancerous cell populations stratified as continuous hypoxic state using Buffa score highlighting CTCF expression and SLC2A3 expression D) Schematic representation of targeting the CTCF motif present in the SLC2A3/GLUT3 promoter region by <t>dCas9-DNMT3A</t> with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy E-G) E and F) MeDIP-qPCR and CTCF-ChIP-qPCR on GLUT3 promoter E) MCF7 and F) MDA-MB-231 (G) immunoblot of GLUT3 in MCF7 and MDA-MB-231cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia (H) Schematic showing hypoxia-driven epigenetic and transcriptional regulation of GLUT3 expression in breast cancer. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired, two-tailed Welch’s Two-Sample t-test (A), Co-expression was assessed using Fisher’s exact test (odds ratio [OR] = 1.80, p < 2.2 × 10⁻¹⁶) (C), unpaired two-tailed Student’s t-tests (F and G), *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
    Dcas9 Dnmt3a Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas9+dnmt3a/DNMT3A-dCas9+(Plasmid+%23100090)/pm41620608-262-10-16
    Average 95 stars, based on 1 article reviews
    dcas9 dnmt3a plasmid - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    93
    Addgene inc m3 dcas9 dnmt3a dnmt3l
    CTCF is required for optimal GLUT3 expression under hypoxia. A) mRNA expression of glycolysis genes in sh_control under normoxia and hypoxia and sh_CTCF under hypoxia in MCF7 cells inferred from CTCF depletion RNA-seq B) genome browser view of SLC2A3 loci of CTCF-ChIP-seq and RNA-seq under normoxia and hypoxia and of RNA-seq in shcontrol and shCTCF under hypoxia in MCF7 cells C) UMAP plot of breast epithelial cancerous cell populations stratified as continuous hypoxic state using Buffa score highlighting CTCF expression and SLC2A3 expression D) Schematic representation of targeting the CTCF motif present in the SLC2A3/GLUT3 promoter region by <t>dCas9-DNMT3A</t> with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy E-G) E and F) MeDIP-qPCR and CTCF-ChIP-qPCR on GLUT3 promoter E) MCF7 and F) MDA-MB-231 (G) immunoblot of GLUT3 in MCF7 and MDA-MB-231cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia (H) Schematic showing hypoxia-driven epigenetic and transcriptional regulation of GLUT3 expression in breast cancer. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired, two-tailed Welch’s Two-Sample t-test (A), Co-expression was assessed using Fisher’s exact test (odds ratio [OR] = 1.80, p < 2.2 × 10⁻¹⁶) (C), unpaired two-tailed Student’s t-tests (F and G), *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
    M3 Dcas9 Dnmt3a Dnmt3l, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas9+dnmt3a/pGSTag+(Plasmid+%2321877)/pm41620608-257-1-3
    Average 93 stars, based on 1 article reviews
    m3 dcas9 dnmt3a dnmt3l - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Addgene inc m3 dcas9 dnmt3a dnmt3a
    CTCF is required for optimal GLUT3 expression under hypoxia. A) mRNA expression of glycolysis genes in sh_control under normoxia and hypoxia and sh_CTCF under hypoxia in MCF7 cells inferred from CTCF depletion RNA-seq B) genome browser view of SLC2A3 loci of CTCF-ChIP-seq and RNA-seq under normoxia and hypoxia and of RNA-seq in shcontrol and shCTCF under hypoxia in MCF7 cells C) UMAP plot of breast epithelial cancerous cell populations stratified as continuous hypoxic state using Buffa score highlighting CTCF expression and SLC2A3 expression D) Schematic representation of targeting the CTCF motif present in the SLC2A3/GLUT3 promoter region by <t>dCas9-DNMT3A</t> with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy E-G) E and F) MeDIP-qPCR and CTCF-ChIP-qPCR on GLUT3 promoter E) MCF7 and F) MDA-MB-231 (G) immunoblot of GLUT3 in MCF7 and MDA-MB-231cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia (H) Schematic showing hypoxia-driven epigenetic and transcriptional regulation of GLUT3 expression in breast cancer. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired, two-tailed Welch’s Two-Sample t-test (A), Co-expression was assessed using Fisher’s exact test (odds ratio [OR] = 1.80, p < 2.2 × 10⁻¹⁶) (C), unpaired two-tailed Student’s t-tests (F and G), *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
    M3 Dcas9 Dnmt3a Dnmt3a, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas9+dnmt3a/pGSTag+(Plasmid+%2321877)/pm41620608-256-0-2
    Average 93 stars, based on 1 article reviews
    m3 dcas9 dnmt3a dnmt3a - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    Addgene inc dcas9 nls dnmt3a
    CTCF is required for optimal GLUT3 expression under hypoxia. A) mRNA expression of glycolysis genes in sh_control under normoxia and hypoxia and sh_CTCF under hypoxia in MCF7 cells inferred from CTCF depletion RNA-seq B) genome browser view of SLC2A3 loci of CTCF-ChIP-seq and RNA-seq under normoxia and hypoxia and of RNA-seq in shcontrol and shCTCF under hypoxia in MCF7 cells C) UMAP plot of breast epithelial cancerous cell populations stratified as continuous hypoxic state using Buffa score highlighting CTCF expression and SLC2A3 expression D) Schematic representation of targeting the CTCF motif present in the SLC2A3/GLUT3 promoter region by <t>dCas9-DNMT3A</t> with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy E-G) E and F) MeDIP-qPCR and CTCF-ChIP-qPCR on GLUT3 promoter E) MCF7 and F) MDA-MB-231 (G) immunoblot of GLUT3 in MCF7 and MDA-MB-231cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia (H) Schematic showing hypoxia-driven epigenetic and transcriptional regulation of GLUT3 expression in breast cancer. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired, two-tailed Welch’s Two-Sample t-test (A), Co-expression was assessed using Fisher’s exact test (odds ratio [OR] = 1.80, p < 2.2 × 10⁻¹⁶) (C), unpaired two-tailed Student’s t-tests (F and G), *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
    Dcas9 Nls Dnmt3a, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas9+dnmt3a/DNMT3A-dCas9+(Plasmid+%23100090)/us12522823-2126-22-31
    Average 95 stars, based on 1 article reviews
    dcas9 nls dnmt3a - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Addgene inc dcas9 dnmt3a p2a egfp fragment
    CTCF is required for optimal GLUT3 expression under hypoxia. A) mRNA expression of glycolysis genes in sh_control under normoxia and hypoxia and sh_CTCF under hypoxia in MCF7 cells inferred from CTCF depletion RNA-seq B) genome browser view of SLC2A3 loci of CTCF-ChIP-seq and RNA-seq under normoxia and hypoxia and of RNA-seq in shcontrol and shCTCF under hypoxia in MCF7 cells C) UMAP plot of breast epithelial cancerous cell populations stratified as continuous hypoxic state using Buffa score highlighting CTCF expression and SLC2A3 expression D) Schematic representation of targeting the CTCF motif present in the SLC2A3/GLUT3 promoter region by <t>dCas9-DNMT3A</t> with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy E-G) E and F) MeDIP-qPCR and CTCF-ChIP-qPCR on GLUT3 promoter E) MCF7 and F) MDA-MB-231 (G) immunoblot of GLUT3 in MCF7 and MDA-MB-231cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia (H) Schematic showing hypoxia-driven epigenetic and transcriptional regulation of GLUT3 expression in breast cancer. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired, two-tailed Welch’s Two-Sample t-test (A), Co-expression was assessed using Fisher’s exact test (odds ratio [OR] = 1.80, p < 2.2 × 10⁻¹⁶) (C), unpaired two-tailed Student’s t-tests (F and G), *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
    Dcas9 Dnmt3a P2a Egfp Fragment, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcas9+dnmt3a/DNMT3A-dCas9+(Plasmid+%23100090)/pm41372159-178-4-12
    Average 95 stars, based on 1 article reviews
    dcas9 dnmt3a p2a egfp fragment - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    CTCF is required for optimal GLUT3 expression under hypoxia. A) mRNA expression of glycolysis genes in sh_control under normoxia and hypoxia and sh_CTCF under hypoxia in MCF7 cells inferred from CTCF depletion RNA-seq B) genome browser view of SLC2A3 loci of CTCF-ChIP-seq and RNA-seq under normoxia and hypoxia and of RNA-seq in shcontrol and shCTCF under hypoxia in MCF7 cells C) UMAP plot of breast epithelial cancerous cell populations stratified as continuous hypoxic state using Buffa score highlighting CTCF expression and SLC2A3 expression D) Schematic representation of targeting the CTCF motif present in the SLC2A3/GLUT3 promoter region by dCas9-DNMT3A with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy E-G) E and F) MeDIP-qPCR and CTCF-ChIP-qPCR on GLUT3 promoter E) MCF7 and F) MDA-MB-231 (G) immunoblot of GLUT3 in MCF7 and MDA-MB-231cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia (H) Schematic showing hypoxia-driven epigenetic and transcriptional regulation of GLUT3 expression in breast cancer. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired, two-tailed Welch’s Two-Sample t-test (A), Co-expression was assessed using Fisher’s exact test (odds ratio [OR] = 1.80, p < 2.2 × 10⁻¹⁶) (C), unpaired two-tailed Student’s t-tests (F and G), *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.

    Journal: bioRxiv

    Article Title: A CTCF-LDHB axis converts nuclear lactate availability into an H3K18 acylation switch that directs alternative splicing in hypoxic breast cancer

    doi: 10.64898/2026.10.27.762200

    Figure Lengend Snippet: CTCF is required for optimal GLUT3 expression under hypoxia. A) mRNA expression of glycolysis genes in sh_control under normoxia and hypoxia and sh_CTCF under hypoxia in MCF7 cells inferred from CTCF depletion RNA-seq B) genome browser view of SLC2A3 loci of CTCF-ChIP-seq and RNA-seq under normoxia and hypoxia and of RNA-seq in shcontrol and shCTCF under hypoxia in MCF7 cells C) UMAP plot of breast epithelial cancerous cell populations stratified as continuous hypoxic state using Buffa score highlighting CTCF expression and SLC2A3 expression D) Schematic representation of targeting the CTCF motif present in the SLC2A3/GLUT3 promoter region by dCas9-DNMT3A with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy E-G) E and F) MeDIP-qPCR and CTCF-ChIP-qPCR on GLUT3 promoter E) MCF7 and F) MDA-MB-231 (G) immunoblot of GLUT3 in MCF7 and MDA-MB-231cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia (H) Schematic showing hypoxia-driven epigenetic and transcriptional regulation of GLUT3 expression in breast cancer. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired, two-tailed Welch’s Two-Sample t-test (A), Co-expression was assessed using Fisher’s exact test (odds ratio [OR] = 1.80, p < 2.2 × 10⁻¹⁶) (C), unpaired two-tailed Student’s t-tests (F and G), *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.

    Article Snippet: Nontargeting sgRNA containing dCas9-DNMT3A vector (Addgene, 71830) was used along with the dCas9-DNMT3A system as a control.

    Techniques: Expressing, Control, RNA Sequencing, ChIP-sequencing, Methylation, Methylated DNA Immunoprecipitation, ChIP-qPCR, Western Blot, Transfection, Comparison, Two Tailed Test

    CTCF drives LDHB expression in TNBC. A) OCR analysis of MCF7 and MDA-MB-231 cells under normoxia and hypoxia B and C) OCR analysis of sh_control and sh_CTCF under hypoxia in B) MCF7 C) MDA-MB-231 cells. Cells were detected at basal level, followed by adding oligomycin (1.5µM), FCCP (0.5μM), and Rot/AA (0.5μM) D) genome browser view of LDHB loci of CTCF-ChIP-seq and RNA-seq under normoxia post 6 hours in MCF7 and MDA-MB-231 cells E) CTCF-ChIP-qPCR at LDHB promoter under normoxia and hypoxia in MCF7 and MDA-MB-231 cell lines F) Immunoblot of HIF1α and LDHB in normoxic and hypoxic MCF7 and MDA-MB-231 cells G) H3K27me2- and H3K27ac-ChIP-qPCR at LDHB promoter under normoxia and hypoxia in MCF7 and MDA-MB-231 cell lines H) Schematic representation of targeting the LDHB promoter by dCas9-DNMT3A with sgRNAs against CTCF to maintain methylation I and J) I) MeDIP-qPCR and CTCF-ChIP-qPCR on LDHB promoter and J) Immunoblot of LDHB in MDA-MB-231 cells transfected with dCas9-DNMT3A-sgCTCF versus dCas9-DNMT3A-sgControl. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired two-tailed Student’s t-tests (E, G, I), ns non-significant, *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.

    Journal: bioRxiv

    Article Title: A CTCF-LDHB axis converts nuclear lactate availability into an H3K18 acylation switch that directs alternative splicing in hypoxic breast cancer

    doi: 10.64898/2026.10.27.762200

    Figure Lengend Snippet: CTCF drives LDHB expression in TNBC. A) OCR analysis of MCF7 and MDA-MB-231 cells under normoxia and hypoxia B and C) OCR analysis of sh_control and sh_CTCF under hypoxia in B) MCF7 C) MDA-MB-231 cells. Cells were detected at basal level, followed by adding oligomycin (1.5µM), FCCP (0.5μM), and Rot/AA (0.5μM) D) genome browser view of LDHB loci of CTCF-ChIP-seq and RNA-seq under normoxia post 6 hours in MCF7 and MDA-MB-231 cells E) CTCF-ChIP-qPCR at LDHB promoter under normoxia and hypoxia in MCF7 and MDA-MB-231 cell lines F) Immunoblot of HIF1α and LDHB in normoxic and hypoxic MCF7 and MDA-MB-231 cells G) H3K27me2- and H3K27ac-ChIP-qPCR at LDHB promoter under normoxia and hypoxia in MCF7 and MDA-MB-231 cell lines H) Schematic representation of targeting the LDHB promoter by dCas9-DNMT3A with sgRNAs against CTCF to maintain methylation I and J) I) MeDIP-qPCR and CTCF-ChIP-qPCR on LDHB promoter and J) Immunoblot of LDHB in MDA-MB-231 cells transfected with dCas9-DNMT3A-sgCTCF versus dCas9-DNMT3A-sgControl. Data represent three technical replicates from pooled samples. Data are mean ± SEM, statistical significance was determined using unpaired two-tailed Student’s t-tests (E, G, I), ns non-significant, *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.

    Article Snippet: Nontargeting sgRNA containing dCas9-DNMT3A vector (Addgene, 71830) was used along with the dCas9-DNMT3A system as a control.

    Techniques: Expressing, Analysis, Control, ChIP-sequencing, RNA Sequencing, ChIP-qPCR, Western Blot, Methylation, Methylated DNA Immunoprecipitation, Transfection, Two Tailed Test

    A CTCF-ERα complex represses LDHB in non-TNBC via modulating epigenetic landscape on LDHB promoter. A) genome browser view of LDHB loci of CTCF-ChIP-seq and ERα-ChIP-seq in MCF7 cells under normoxia B) ERα-ChIP-qPCR in CTCF depletion under hypoxia in comparison to sh_control under normoxic and hypoxic MCF7 cells C) MCF7 and MDA-MB-231 cells were co-transfected with wild type or CTCF or ERα or CTCF/ ERα mutant LDHB promoter luciferase construct (−337 to +115) and pRL-TK Renilla under normoxia D) Immunoblot of CTCF, ERα (to confirm overexpression of ERα) and LDHB in MDA-MB-231 cells with ectopically expressed either empty vector (EV) or ERα in MDA-MB-231 cells E) CTCF ChIP-seq signals at ESR1 promoter in MCF7 and MDA-MB-231 cells F) Schematic representation of targeting the ESR1 promoter by dCas9-DNMT3A with sgRNAs against CTCF to maintain methylation G and H) G) MeDIP-qPCR and CTCF-ChIP-qPCR on ESR1 promoter and H) Immunoblot of ERα and LDHB in MCF7 cells transfected with dCas9-DNMT3A-sgCTCF_ESR1 versus dCas9-DNMT3A-sgcontrol I) MeDIP-qPCR and CTCF-ChIP-qPCR on LDHB promoter in MCF7 cells transfected with dCas9-DNMT3A-sgCTCF_ESR1 versus dCas9-DNMT3A-sgcontrol J) Immunoblot of LDHB in MCF7 cells treated with Tamoxifen in comparison to the control cells under normoxia K) ERα, CTCF, EZH2, H3K27me2 and H3K27ac-ChIP-qPCR on LDHB promoter in MCF7 cells treated with Tamoxifen in comparison to the control cells under normoxia and hypoxia L) MCF7 and MDA-MB-231 cells were co-transfected with wild type LDHB promoter luciferase construct (−337 to +115) and pRL-TK Renilla and treated with Tamoxifen under normoxic condition M) Schematic showing CTCF-driven epigenetic and transcriptional regulation of LDHB expression in TNBC and non-TNBC breast cancer. Data are mean ± SEM, statistical significance was determined using one-way ANOVA with Tukey’s multiple comparisons test (B, C, L, M), unpaired two-tailed Student’s t-tests (G, J), ns non-significant, *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.

    Journal: bioRxiv

    Article Title: A CTCF-LDHB axis converts nuclear lactate availability into an H3K18 acylation switch that directs alternative splicing in hypoxic breast cancer

    doi: 10.64898/2026.10.27.762200

    Figure Lengend Snippet: A CTCF-ERα complex represses LDHB in non-TNBC via modulating epigenetic landscape on LDHB promoter. A) genome browser view of LDHB loci of CTCF-ChIP-seq and ERα-ChIP-seq in MCF7 cells under normoxia B) ERα-ChIP-qPCR in CTCF depletion under hypoxia in comparison to sh_control under normoxic and hypoxic MCF7 cells C) MCF7 and MDA-MB-231 cells were co-transfected with wild type or CTCF or ERα or CTCF/ ERα mutant LDHB promoter luciferase construct (−337 to +115) and pRL-TK Renilla under normoxia D) Immunoblot of CTCF, ERα (to confirm overexpression of ERα) and LDHB in MDA-MB-231 cells with ectopically expressed either empty vector (EV) or ERα in MDA-MB-231 cells E) CTCF ChIP-seq signals at ESR1 promoter in MCF7 and MDA-MB-231 cells F) Schematic representation of targeting the ESR1 promoter by dCas9-DNMT3A with sgRNAs against CTCF to maintain methylation G and H) G) MeDIP-qPCR and CTCF-ChIP-qPCR on ESR1 promoter and H) Immunoblot of ERα and LDHB in MCF7 cells transfected with dCas9-DNMT3A-sgCTCF_ESR1 versus dCas9-DNMT3A-sgcontrol I) MeDIP-qPCR and CTCF-ChIP-qPCR on LDHB promoter in MCF7 cells transfected with dCas9-DNMT3A-sgCTCF_ESR1 versus dCas9-DNMT3A-sgcontrol J) Immunoblot of LDHB in MCF7 cells treated with Tamoxifen in comparison to the control cells under normoxia K) ERα, CTCF, EZH2, H3K27me2 and H3K27ac-ChIP-qPCR on LDHB promoter in MCF7 cells treated with Tamoxifen in comparison to the control cells under normoxia and hypoxia L) MCF7 and MDA-MB-231 cells were co-transfected with wild type LDHB promoter luciferase construct (−337 to +115) and pRL-TK Renilla and treated with Tamoxifen under normoxic condition M) Schematic showing CTCF-driven epigenetic and transcriptional regulation of LDHB expression in TNBC and non-TNBC breast cancer. Data are mean ± SEM, statistical significance was determined using one-way ANOVA with Tukey’s multiple comparisons test (B, C, L, M), unpaired two-tailed Student’s t-tests (G, J), ns non-significant, *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.

    Article Snippet: Nontargeting sgRNA containing dCas9-DNMT3A vector (Addgene, 71830) was used along with the dCas9-DNMT3A system as a control.

    Techniques: ChIP-sequencing, ChIP-qPCR, Comparison, Control, Transfection, Mutagenesis, Luciferase, Construct, Western Blot, Over Expression, Plasmid Preparation, Methylation, Methylated DNA Immunoprecipitation, Expressing, Two Tailed Test

    CTCF and H3K18la together direct TACC3 splicing towards exon 3 exclusion in the non-TNBC. A) Schematic representation of targeting the CTCF motif at CBSDS loci of TACC3 gene region by dCas9-DNMT3A with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy B) MeDIP-qPCR and CTCF-ChIP-qPCR at CBSDS loci of TACC3 gene region (C) alternative splicing analysis of TACC3 D) qPCR analysis of alternative splicing of TACC3 E) H3K18la and Pol II-ChIP-qPCR at CBSDS loci of TACC3 gene region in MCF7 cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia F) Schematic representation of targeting the CTCF motif at CBSDS loci of TACC3 gene region by dCas9-HDAC3 with specific sgRNA used in (A) to remove H3K18la G) MeDIP-qPCR and CTCF-ChIP-qPCR at CBSDS loci of TACC3 gene region (H) H3K18la and Pol II-ChIP-qPCR I) alternative splicing analysis of TACC3 J) qPCR analysis of alternative splicing of TACC3 at CBSDS loci of TACC3 gene region in MCF7 cells transfected with dCas9-HDAC3-sgCTCF in comparison to the sgcontrol under hypoxia K) Schematic representation of targeting the CTCF motif at CBSDS loci of TACC3 gene region by dCas9-AARS1 with specific sgRNA used in (A) to add H3K18la L) H3K18la-and CTCF-ChIP-qPCR (M) MeDIP-qPCR at CBSDS loci of TACC3 gene region N) qPCR analysis of alternative splicing of TACC3 O) alternative splicing analysis of TACC3 in MCF7 cells transfected with dCas9-AARS1-sgCTCF in comparison to the sgcontrol either supplemented solvent or with 20mm NaLa under normoxia. Data are mean ± SEM, statistical significance was determined using unpaired two-tailed Student’s t-tests (B, D, E, G, H, J), one-way ANOVA with Tukey’s multiple comparisons test (L, M, N), ns non-significant, *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.

    Journal: bioRxiv

    Article Title: A CTCF-LDHB axis converts nuclear lactate availability into an H3K18 acylation switch that directs alternative splicing in hypoxic breast cancer

    doi: 10.64898/2026.10.27.762200

    Figure Lengend Snippet: CTCF and H3K18la together direct TACC3 splicing towards exon 3 exclusion in the non-TNBC. A) Schematic representation of targeting the CTCF motif at CBSDS loci of TACC3 gene region by dCas9-DNMT3A with specific sgRNA against CTCF to maintain methylation and suppress CTCF occupancy B) MeDIP-qPCR and CTCF-ChIP-qPCR at CBSDS loci of TACC3 gene region (C) alternative splicing analysis of TACC3 D) qPCR analysis of alternative splicing of TACC3 E) H3K18la and Pol II-ChIP-qPCR at CBSDS loci of TACC3 gene region in MCF7 cells transfected with dCas9-DNMT3A-sgCTCF in comparison to the sgcontrol under hypoxia F) Schematic representation of targeting the CTCF motif at CBSDS loci of TACC3 gene region by dCas9-HDAC3 with specific sgRNA used in (A) to remove H3K18la G) MeDIP-qPCR and CTCF-ChIP-qPCR at CBSDS loci of TACC3 gene region (H) H3K18la and Pol II-ChIP-qPCR I) alternative splicing analysis of TACC3 J) qPCR analysis of alternative splicing of TACC3 at CBSDS loci of TACC3 gene region in MCF7 cells transfected with dCas9-HDAC3-sgCTCF in comparison to the sgcontrol under hypoxia K) Schematic representation of targeting the CTCF motif at CBSDS loci of TACC3 gene region by dCas9-AARS1 with specific sgRNA used in (A) to add H3K18la L) H3K18la-and CTCF-ChIP-qPCR (M) MeDIP-qPCR at CBSDS loci of TACC3 gene region N) qPCR analysis of alternative splicing of TACC3 O) alternative splicing analysis of TACC3 in MCF7 cells transfected with dCas9-AARS1-sgCTCF in comparison to the sgcontrol either supplemented solvent or with 20mm NaLa under normoxia. Data are mean ± SEM, statistical significance was determined using unpaired two-tailed Student’s t-tests (B, D, E, G, H, J), one-way ANOVA with Tukey’s multiple comparisons test (L, M, N), ns non-significant, *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.

    Article Snippet: Nontargeting sgRNA containing dCas9-DNMT3A vector (Addgene, 71830) was used along with the dCas9-DNMT3A system as a control.

    Techniques: Methylation, Methylated DNA Immunoprecipitation, ChIP-qPCR, Alternative Splicing, Analysis, Transfection, Comparison, Solvent, Two Tailed Test